We serve Chemical Name:2-oxopyrrolidine-3-carboxylic acid CAS:96905-67-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-oxopyrrolidine-3-carboxylic acid
CAS.NO:96905-67-8
Synonyms:3-Pyrrolidinecarboxylic acid,2-oxo;2-OXO-3-PYRROLIDINECARBOXYLIC ACID;2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID
Molecular Formula:C5H7NO3
Molecular Weight:129.11400
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:453.134ºC at 760 mmHg
Density:1.381g/cm3
Index of Refraction:1.512
PSA:69.89000
Exact Mass:129.04300
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Pyrrolidinecarboxylic acid,2-oxo chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-OXO-3-PYRROLIDINECARBOXYLIC ACID Use and application,2-OXO-3-PYRROLIDINECARBOXYLIC ACID technical grade,usp/ep/jp grade.
Related News: Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 1-Ethoxycarbonyl-4-oxo-5-(β-methoxy-carbonyl-ethyl)-piperidin-3-carbonsaeure-methylester manufacturers The company will see an immediate $6 billion bump to its topline thanks to Alexion’s C5 inhibitors, used to treat rare diseases like paroxysmal nocturnal hemoglobinuria. 1,3-Benzenediol, 5,5′,5′-[1,3,5-triazine-2,4,6-triyltris(oxy)]tris- suppliers The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005. 4-piperidin-1-yl-phthalic acid diethyl ester vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 1-Ethoxycarbonyl-4-oxo-5-(β-methoxy-carbonyl-ethyl)-piperidin-3-carbonsaeure-methylester manufacturers The company will see an immediate $6 billion bump to its topline thanks to Alexion’s C5 inhibitors, used to treat rare diseases like paroxysmal nocturnal hemoglobinuria. 1,3-Benzenediol, 5,5′,5′-[1,3,5-triazine-2,4,6-triyltris(oxy)]tris- suppliers The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005. 4-piperidin-1-yl-phthalic acid diethyl ester vendor & factory.
